BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 38159337)

  • 21. Phase 2 study of dose-intense temozolomide in recurrent glioblastoma.
    Norden AD; Lesser GJ; Drappatz J; Ligon KL; Hammond SN; Lee EQ; Reardon DR; Fadul CE; Plotkin SR; Batchelor TT; Zhu JJ; Beroukhim R; Muzikansky A; Doherty L; Lafrankie D; Smith K; Tafoya V; Lis R; Stack EC; Rosenfeld MR; Wen PY
    Neuro Oncol; 2013 Jul; 15(7):930-5. PubMed ID: 23553268
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial.
    Weller M; Tabatabai G; Kästner B; Felsberg J; Steinbach JP; Wick A; Schnell O; Hau P; Herrlinger U; Sabel MC; Wirsching HG; Ketter R; Bähr O; Platten M; Tonn JC; Schlegel U; Marosi C; Goldbrunner R; Stupp R; Homicsko K; Pichler J; Nikkhah G; Meixensberger J; Vajkoczy P; Kollias S; Hüsing J; Reifenberger G; Wick W;
    Clin Cancer Res; 2015 May; 21(9):2057-64. PubMed ID: 25655102
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Afatinib and radiotherapy, with or without temozolomide, in patients with newly diagnosed glioblastoma: results of a phase I trial.
    Saran F; Welsh L; James A; McBain C; Gattamaneni R; Jefferies S; Harris F; Pemberton K; Schaible J; Bender S; Cseh A; Brada M
    J Neurooncol; 2021 Dec; 155(3):307-317. PubMed ID: 34787778
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse.
    Brada M; Hoang-Xuan K; Rampling R; Dietrich PY; Dirix LY; Macdonald D; Heimans JJ; Zonnenberg BA; Bravo-Marques JM; Henriksson R; Stupp R; Yue N; Bruner J; Dugan M; Rao S; Zaknoen S
    Ann Oncol; 2001 Feb; 12(2):259-66. PubMed ID: 11300335
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma.
    Stupp R; Hegi ME; Neyns B; Goldbrunner R; Schlegel U; Clement PM; Grabenbauer GG; Ochsenbein AF; Simon M; Dietrich PY; Pietsch T; Hicking C; Tonn JC; Diserens AC; Pica A; Hermisson M; Krueger S; Picard M; Weller M
    J Clin Oncol; 2010 Jun; 28(16):2712-8. PubMed ID: 20439646
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Temozolomide in patients with a glioblastoma multiforme: new developments].
    Bromberg JE; Postma TJ
    Ned Tijdschr Geneeskd; 2005 Jun; 149(25):1376-8. PubMed ID: 15997689
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A multicenter phase II study of temozolomide plus disulfiram and copper for recurrent temozolomide-resistant glioblastoma.
    Huang J; Chaudhary R; Cohen AL; Fink K; Goldlust S; Boockvar J; Chinnaiyan P; Wan L; Marcus S; Campian JL
    J Neurooncol; 2019 May; 142(3):537-544. PubMed ID: 30771200
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hypofractionated accelerated radiotherapy (HART) with concurrent and adjuvant temozolomide in newly diagnosed glioblastoma: a phase II randomized trial (HART-GBM trial).
    Mallick S; Kunhiparambath H; Gupta S; Benson R; Sharma S; Laviraj MA; Upadhyay AD; Julka PK; Sharma D; Rath GK
    J Neurooncol; 2018 Oct; 140(1):75-82. PubMed ID: 29936695
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety results of ABT-414 in combination with radiation and temozolomide in newly diagnosed glioblastoma.
    Reardon DA; Lassman AB; van den Bent M; Kumthekar P; Merrell R; Scott AM; Fichtel L; Sulman EP; Gomez E; Fischer J; Lee HJ; Munasinghe W; Xiong H; Mandich H; Roberts-Rapp L; Ansell P; Holen KD; Gan HK
    Neuro Oncol; 2017 Jul; 19(7):965-975. PubMed ID: 28039367
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide.
    Hegi ME; Diserens AC; Godard S; Dietrich PY; Regli L; Ostermann S; Otten P; Van Melle G; de Tribolet N; Stupp R
    Clin Cancer Res; 2004 Mar; 10(6):1871-4. PubMed ID: 15041700
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study.
    Baumert BG; Hegi ME; van den Bent MJ; von Deimling A; Gorlia T; Hoang-Xuan K; Brandes AA; Kantor G; Taphoorn MJB; Hassel MB; Hartmann C; Ryan G; Capper D; Kros JM; Kurscheid S; Wick W; Enting R; Reni M; Thiessen B; Dhermain F; Bromberg JE; Feuvret L; Reijneveld JC; Chinot O; Gijtenbeek JMM; Rossiter JP; Dif N; Balana C; Bravo-Marques J; Clement PM; Marosi C; Tzuk-Shina T; Nordal RA; Rees J; Lacombe D; Mason WP; Stupp R
    Lancet Oncol; 2016 Nov; 17(11):1521-1532. PubMed ID: 27686946
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase 1 trial of ralimetinib (LY2228820) with radiotherapy plus concomitant temozolomide in the treatment of newly diagnosed glioblastoma.
    Biau J; Thivat E; Chautard E; Stefan D; Boone M; Chauffert B; Bourgne C; Richard D; Molnar I; Levesque S; Bellini R; Kwiatkowski F; Karayan-Tapon L; Verrelle P; Godfraind C; Durando X
    Radiother Oncol; 2021 Jan; 154():227-234. PubMed ID: 32976869
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A phase 1 trial of ABT-510 concurrent with standard chemoradiation for patients with newly diagnosed glioblastoma.
    Nabors LB; Fiveash JB; Markert JM; Kekan MS; Gillespie GY; Huang Z; Johnson MJ; Meleth S; Kuo H; Gladson CL; Fathallah-Shaykh HM
    Arch Neurol; 2010 Mar; 67(3):313-9. PubMed ID: 20212229
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MGMT gene silencing and benefit from temozolomide in glioblastoma.
    Hegi ME; Diserens AC; Gorlia T; Hamou MF; de Tribolet N; Weller M; Kros JM; Hainfellner JA; Mason W; Mariani L; Bromberg JE; Hau P; Mirimanoff RO; Cairncross JG; Janzer RC; Stupp R
    N Engl J Med; 2005 Mar; 352(10):997-1003. PubMed ID: 15758010
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MGMT promoter hypermethylation correlates with a survival benefit from temozolomide in patients with recurrent anaplastic astrocytoma but not glioblastoma.
    Sadones J; Michotte A; Veld P; Chaskis C; Sciot R; Menten J; Joossens EJ; Strauven T; D'Hondt LA; Sartenaer D; Califice SF; Bierau K; Svensson C; De Grève J; Neyns B
    Eur J Cancer; 2009 Jan; 45(1):146-53. PubMed ID: 18945611
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO).
    Brandes AA; Tosoni A; Cavallo G; Bertorelle R; Gioia V; Franceschi E; Biscuola M; Blatt V; Crinò L; Ermani M;
    Br J Cancer; 2006 Nov; 95(9):1155-60. PubMed ID: 17024124
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Short-term radiotherapy followed by adjuvant chemotherapy in poor-prognosis patients with glioblastoma.
    Muni R; Minniti G; Lanzetta G; Caporello P; Frati A; Enrici MM; Marchetti P; Enrici RM
    Tumori; 2010; 96(1):60-4. PubMed ID: 20437859
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme.
    Peereboom DM; Shepard DR; Ahluwalia MS; Brewer CJ; Agarwal N; Stevens GH; Suh JH; Toms SA; Vogelbaum MA; Weil RJ; Elson P; Barnett GH
    J Neurooncol; 2010 May; 98(1):93-9. PubMed ID: 19960228
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study.
    Nabors LB; Fink KL; Mikkelsen T; Grujicic D; Tarnawski R; Nam DH; Mazurkiewicz M; Salacz M; Ashby L; Zagonel V; Depenni R; Perry JR; Hicking C; Picard M; Hegi ME; Lhermitte B; Reardon DA
    Neuro Oncol; 2015 May; 17(5):708-17. PubMed ID: 25762461
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Feasibility and safety of extended adjuvant temozolomide beyond six cycles for patients with glioblastoma.
    Hsieh SY; Chan DT; Kam MK; Loong HH; Tsang WK; Poon DM; Ng SC; Poon WS
    Hong Kong Med J; 2017 Dec; 23(6):594-8. PubMed ID: 28798282
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.